Vis enkel innførsel

dc.contributor.authorHagen, Kristen
dc.contributor.authorNordahl, Håkon
dc.contributor.authorLaunes, Gunvor
dc.contributor.authorKvale, Gerd
dc.contributor.authorÖst, Lars Gøran
dc.contributor.authorHystad, Sigurd
dc.contributor.authorHansen, Bjarne
dc.contributor.authorSolem, Stian
dc.date.accessioned2022-02-08T10:28:21Z
dc.date.available2022-02-08T10:28:21Z
dc.date.created2021-09-20T15:33:11Z
dc.date.issued2021
dc.identifier.citationFrontiers in Psychiatry. 2021, 12:625631 1-8.en_US
dc.identifier.issn1664-0640
dc.identifier.urihttps://hdl.handle.net/11250/2977672
dc.description.abstractInsomnia is a substantial problem in patients with obsessive-compulsive disorder (OCD). There is, however, a lack of studies investigating changes in concurrent symptoms of insomnia in OCD after concentrated treatment. A recent randomized controlled trial randomized participants to the Bergen 4-day treatment (B4DT, n = 16), or 12 weeks of unguided self-help (SH, n = 16), or waitlist (WL, n = 16). Patients from the SH- and WL-group who wanted further treatment after the 12 weeks were then offered the B4DT (total of 42 patients treated with the B4DT). There were no significant differences in symptoms of insomnia between the conditions at post-treatment, but a significant moderate improvement at 3-month follow-up for patients who received the B4DT. Insomnia was not associated with OCD-treatment outcome, and change in symptoms of insomnia was mainly related to changes in depressive symptoms. The main conclusion is that concentrated exposure treatment is effective irrespective of comorbid insomnia, and that insomnia problems are moderately reduced following treatment.en_US
dc.language.isoengen_US
dc.publisherFrontiers Mediaen_US
dc.relation.urihttps://www.frontiersin.org/articles/10.3389/fpsyt.2021.625631/full
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleDoes Concentrated Exposure Treatment for Obsessive-Compulsive Disorder Improve Insomnia Symptoms? Results From a Randomized Controlled Trialen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber1-8en_US
dc.source.volume12:625631en_US
dc.source.journalFrontiers in Psychiatryen_US
dc.identifier.doi10.3389/fpsyt.2021.625631
dc.identifier.cristin1936202
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal